2012
DOI: 10.1128/aac.00711-12
|View full text |Cite
|
Sign up to set email alerts
|

Substitutions at Position 105 in SHV Family β-Lactamases Decrease Catalytic Efficiency and Cause Inhibitor Resistance

Abstract: Ambler position 105 in class A ␤-lactamases is implicated in resistance to clavulanic acid, although no clinical isolates with mutations at this site have been reported. We hypothesized that Y105 is important in resistance to clavulanic acid because changes in positioning of the inhibitor for ring oxygen protonation could occur. In addition, resistance to bicyclic 6-methylidene penems, which are interesting structural probes that inhibit all classes of serine ␤-lactamases with nanomolar affinity, might emerge … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
11
0

Year Published

2013
2013
2020
2020

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 10 publications
(11 citation statements)
references
References 45 publications
0
11
0
Order By: Relevance
“…The commercially available β-lactamase inhibitors (BLIs), clavulanic acid, sulbactam and tazobactam, are only effective against class A β-lactamases. However, their combinations with β-lactam antibiotics are still effective, despite the emergence of resistance, either because of gene-dosage effect (Martinez et al, 1987, 1989; Reguera et al, 1991), either because of mutations that make β-lactamase resilient to inhibition (Blazquez et al, 1993; Canica et al, 1998; Salverda et al, 2010; Frase et al, 2011; Li et al, 2012). …”
Section: Inhibitors Of Resistance Determinantsmentioning
confidence: 99%
“…The commercially available β-lactamase inhibitors (BLIs), clavulanic acid, sulbactam and tazobactam, are only effective against class A β-lactamases. However, their combinations with β-lactam antibiotics are still effective, despite the emergence of resistance, either because of gene-dosage effect (Martinez et al, 1987, 1989; Reguera et al, 1991), either because of mutations that make β-lactamase resilient to inhibition (Blazquez et al, 1993; Canica et al, 1998; Salverda et al, 2010; Frase et al, 2011; Li et al, 2012). …”
Section: Inhibitors Of Resistance Determinantsmentioning
confidence: 99%
“…After discarding the supernatant, the pellet was resuspended in 80 l of 5ϫ sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) loading dye and boiled at 100°C for 10 min. Immunoblotting was performed with the samples as described previously (20). The membrane was probed with rabbit polyclonal anti-CMY-2 antibody at 1.0 g/ml in blocking buffer, and bands were detected with protein G-horseradish peroxidase conjugate (Bio-Rad).…”
Section: Mutagenesismentioning
confidence: 99%
“…CMY-2 and N152G, -S, and -T CMY-2 ␤-lactamases were expressed in E. coli AS226-51 cells (Invitrogen), derived from a strain that does not produce a chromosomal AmpC ␤-lactamase. As described previously, crude extracts were purified to homogeneity by preparative isoelectric focusing and gel filtration or cation exchange chromatography using a GE Superdex 75 10/300 column with 1ϫ phosphatebuffered saline (pH 7.4) or GE HiTrap Q HP columns with 50 mM HEPES (pH 7.0) and elution buffer consisting of 50 mM HEPES and 1 M NaCl (pH 7.0) (20). Protein purity was assessed with SDS-PAGE and was Ͼ95%.…”
Section: Mutagenesismentioning
confidence: 99%
See 1 more Smart Citation
“…Variable expression of ESBLs was described several years ago, particularly with SHV variants, affecting the hydrolysis of cephalosporins and MIC values (18). This could also eventually affect the hydrolysis of HMRZ-86, a fact that has been shown with nitrocefin and in vitro variants obtained by mutagenesis of bla SHV-1 (19). On the other hand, results for carbapenemase producers (n ϭ 67) were mainly positive (92.5% [62/67 isolates]), including results for producers of OXA-48, an enzyme with minor hydrolytic activity against extended-spectrum cephalosporins (20).…”
mentioning
confidence: 99%